Drugs / iNTS-TCV
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05480800 | Sep 2022 → Sep 2024 | salmonellosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07286370 | Apr 2026 → Apr 2028 expected | salmonellosis | GlaxoSmithKline | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iNTS-TCV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05480800 ↗ |
| Modality | Vaccine | “iNTS-TCV low dose vaccine” NCT05480800 ↗ |